Clinical Trial: Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07283679) titled 'Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma' on Dec. 11.

Brief Summary: The goal of this clinical research study is to learn if ONC-PluReceptor NK cell therapy (combined with the monoclonal antibody therapies epcoritamab and tafasitamab) can help to control relapsed or refractory B-cell Non-Hodgkin Lymphoma. The safety of this treatment will also be studied.

Study Start Date: June 01, 2026

Study Type: INTERVENTIONAL

Condition: Recurrent B-Cell Non-Hodgkin Lymphoma Refractory B-cell Non-Hodgkin Lymphoma

Intervention: DRUG: ON...